



**PATIENT**

Turner Hubert

**SPECIES**

Canine

**BREED**

Cocker Spaniel

**SEX**

Male Neutered

**AGE**

10 years

**WEIGHT**

36.7lbs

**INTERPRETED BY**

Maggie Machen  
Lamy, DVM  
DACVIM (Cardiology)

**PRESENTING CLINICAL SIGNS**

History: Recheck echo. History chronic valvular disease - Stage B2. Current presentation: Turner is doing well at home. He has recently started some cephalexin for a skin issue. Goes for 1/2-mile walks twice a day. He is eating well. On exam: NSR, grade IV/VI murmur with PMI left apical area radiating to right, PSS, lung fields clear. BP: 110-120 mmHg. Current medications: 1) Pimobendan/vetmedin 5mg 3/4 tab twice a day 2) Gabapentin 100mg 2 capsules for visit today 3) Trazadone 100mg 1/2 tab for visit today 4) Cephalexin 500mg 1 capsule twice a day \*Sedated with gabapentin/trazadone.  
-Pertinent previous echo findings (10/5/21 Maggie Machen Lamy, DVM, DACVIM-cardiology): LA 2.8 cm; LA:Ao 1.7; LV 3.2 cm; moderate LAE; minimal LVE; moderate MR: mild-moderate TR (2.8 m/s); early pulmonary hypertension.

**ECHOCARDIOGRAM FINDINGS**

2D, m-mode, color flow and Doppler imaging is available.  
**Left ventricle:** Mild LV dilation with adequate function. LV wall thicknesses are normal.  
**Left atrium:** The left atrium is moderately dilated.  
**Mitral valve:** The mitral valve is diffusely thickened with mild prolapse into the left atrial lumen. Moderate eccentric mitral regurgitation with a normal velocity.  
**Aortic valve/Aorta:** The aortic valve is normal in morphology and mobility. Normal aortic outflow velocity; laminar flow. No aortic insufficiency.  
**Right ventricle:** Normal right ventricular diameter and morphology indicating no overt evidence of pulmonary arterial hypertension.  
**Right atrium:** Normal RA dimension.  
**Tricuspid valve:** The tricuspid valve appears thickened with septal prolapse and mild tricuspid regurgitation. Velocity consistent with early pulmonary hypertension.  
**Pulmonic valve/Pulmonary artery:** The pulmonic valve is normal in morphology and mobility. No pulmonic insufficiency. Normal RVOT velocity; laminar flow.  
**Pericardium/other:** No pericardial or pleural effusion noted. No obvious cardiac masses.  
**Heart rhythm:** ECG reveals a sinus rhythm with an average HR of 80bpm.

**2-Dimensional Measurements**

Ao diam (cm)	1.9
LA diam (cm)	3.3
LA:Ao (Swe)	1.7
IVS thickness (cm)	0.9
LVID diastole (cm)	3.8
PW thickness (cm)	0.9
LVID systole (cm)	1.7
FS (%)	55

**Doppler Measurements**

PV Vmax (m/s)	1.2
AoV Vmax (m/s)	2.3
MR Vmax (m/s)	6.3
TR Vmax (m/s)	2.2
TR PG (mmHg)	20

**IMAGING PERFORMED BY**

Pamela Harrigan,  
RDCS

**HOSPITAL NAME**

Mass Veterinary Services

**REFERRING VET**

Dr. Masloski

**INVOICE**

24764

**DATE**

6/14/22

**INTERPRETATION OF THE FINDINGS**

Chronic degenerative valve disease persists with relative stability. While both the LA and LV are slightly increased comparatively, the MR and TR are unchanged. No additional issues are identified, such as significant pulmonary hypertension.

Given these findings, continue Pimobendan lifelong. No additional medications are indicated. Assessment of progression in the future will help predict long term outcome, however prognosis is guarded at this stage (B2).



**PATIENT**

Turner Hubert

**SPECIES**

Canine

**BREED**

Cocker Spaniel

**SEX**

Male Neutered

**AGE**

10 years

**WEIGHT**

36.7lbs

**INTERPRETED BY**

Maggie Machen Lamy, DVM  
DACVIM (Cardiology)

**IMAGING PERFORMED BY**

Pamela Harrigan, RDCS

**HOSPITAL NAME**

Mass Veterinary Services

**REFERRING VET**

Dr. Masloski

**INVOICE**

24764

**DATE**

6/14/22


**RECOMMENDATIONS**

- Continue Pimobendan as prescribed.
- Omega fatty acid supplementation and mild salt restriction may be of some long-term benefit.
- Anesthetic risk is considered mild if needed. Cardiac protective drug choices (opioid/benzodiazepine premedication, propofol or alfaxalone induction, isoflurane gas) are recommended. Pre-oxygenate for 5-10 minutes prior to induction. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Mild IV fluid restriction is recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated.
- Monitor for development of a cough, labored breathing, exercise intolerance or collapse episodes.

**PLAN**

- Recommend conservative monitoring with a recheck echocardiogram in 6-8 months, sooner if any development of clinical signs.

**IMAGES**



The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

Maggie Machen Lamy, DVM  
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)  
info@sonopath.com

**Echocardiogram performed by:**

Pamela Harrigan, RDCS  
Pet Animal Ultrasound Service (4paus.com)